Key result
Aortic Mitroflow bioprosthesis shows ~7% early mortality with 27% survival at 18 years.
Why the study?
A multicentre longitudinal evaluation of the Mitroflow pericardial bioprosthesis over 20 years was needed to assess long-term postoperative outcomes and valve-related events.
Cohort (n=1,591)
Yes
The Mitroflow pericardial bioprosthesis provides favorable long-term outcomes with low rates of structural valve degeneration, particularly in patients older than 70 years.
Answers are grounded in this paper and cite their sources.
Supports Mitroflow durability in patients >70 years; observational data leave comparative efficacy versus contemporary valves open.
OBJECTIVE: A multicentre experience with the Mitroflow pericardial bioprosthesis has been evaluated longitudinally over a 20-year period. METHODS: From 1988 through 2008, 1591 patients (mean age, 75.3±6.8 years, and 60.1% female) from 12 centres had a Mitroflow in the aortic position. Concomitant coronary artery bypass was performed in 41.9% (n=666) of patients, urgency/emergency surgery in 9.5% (n=152) and replacement of degenerated prosthesis in 2.3% (n=36). Follow-up (7.447 patient-years) was 99.2% complete. Median follow-up was 61.9 months (interquartile range (IQR) 30.8-90.9 months). The study was carried out following American Association for Thoracic Surgery/Society for Thoracic Surgeons/European Association for Cardio-Thoracic Surgery (AATS/STS/EACTS) Guidelines for reporting valve morbidity and mortality. RESULTS: The early (30-day) mortality was 6.5% (n=104). Actuarial survival rates at 10, 15 and 18 years were 53%, 34% and 27%, respectively (2.2 patient/year). Re-operation was required in 96 patients (5.9%), of whom 59 patients (3.7%) for structural valve degeneration. Actuarial freedom from prosthetic valve degeneration at 18 years was 65.5% (78% in patients>70 years) with a linearised rate of 1.4 patient/year (0.8 patient/year in patients>70 years). At 18 years, freedom from embolism was 82% (0.9 patient/year), freedom from valve endocarditis was 89% (0.6 patient/year) and freedom from bleeding episodes was 95% (0.2 patient/year), respectively. CONCLUSIONS: This independent multicentre study indicates that the Mitroflow pericardial bioprosthesis provides favourable long-term postoperative results with a low rate of valve-related events and need of re-intervention, particularly in patients older than 70 years.
No takes yet. Share an insight, caveat, or question.
A 2010 study conducted a cohort in Aortic valve replacement (n=1,591). Mitroflow pericardial bioprosthesis was evaluated on Early (30-day) mortality. Mitroflow pericardial bioprosthesis in the aortic position resulted in an early mortality of 6.5% and actuarial survival rates of 53%, 34%, and 27% at 10, 15, and 18 years, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: